Table 2 Demographics and clinical characteristics.

From: Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Characteristics

All patients (n = 32)

Median age, years (range)

69.5 (35–76)

Age, years, N (%)

 

  ≤50

2 (6.3)

  51–64

8 (25.0)

  65–74

19 (59.4)

  ≥75

3 (9.4)

Male, N (%)

20 (62.5)

ECOG performance status, N (%)

 

   0

8 (25.0)

   1

22 (68.8)

   2

2 (6.3)

Median no. of years since diagnosis (range)a

5.25 (0.4–11.3)

ISS stage at initial diagnosis, N (%)

 

   I

5 (15.6)

   II

10 (31.3)

   III

4 (12.5)

   Unknown

13 (40.6)

Median no. of prior therapies (range)

4 (1–8)

Prior therapies, treated: refractoryb, N (%)

 

   Bortezomib

32 (100.0):14 (43.8)

   Carfilzomib

3 (9.4):1 (3.1)

   Ixazomib

11 (34.4):7 (21.9)

   Oprozomib

2 (6.3):1 (3.1)

   Thalidomide

3 (9.4):0 (0)

   Lenalidomide

31 (96.9):18 (56.3)

   Pomalidomide

23 (71.9):18(56.3)

   Daratumumab

22 (68.8):21 (65.6)

   Belantamab mafodotin

1 (3.1):1 (3.1)

   Elotuzumab

10 (31.3):6 (18.8)

   PIsc

32 (100.0):19 (59.4)

   IMiDsd

32 (100.0):24 (75.0)

   Anti-CD38 mAbe

22 (68.8):21 (65.6)

   PI and IMiD and Anti-CD38 mAbf

22 (68.8):12 (37.5)

   ≥2 PIs and ≥2 IMiDs and anti-CD38 mAb

9 (28.1):3 (9.4)

Autologous stem-cell transplantation, N (%)

23 (71.9)

Genetic abnormalities at initial diagnosis or screening, n (%)

 

   del(17p)

9 (28.1)

   t(4;14)

7 (21.9)

   t(14;16)

4 (12.5)

   Gain 1q

4 (12.5)

   Any of del(17p), t(4;14), t(14;16) or gain 1q

17 (53.1)

  1. aYears from the initial diagnosis to C1D1 start date. Fourteen patients had incomplete diagnosis dates, which were imputed as the first day of the year if the month and day were missing, and as the first day of the month if only the day was missing.
  2. bRefractory is defined as prior treatment meeting refractory criteria (best overall response of PD or SD, or disease progression during treatment or within 60 days of the end of treatment, or end of treatment within 60 days of the first dose in STOMP), and no subsequent treatment with PR or better and no refractory criteria met.
  3. cPIs (proteasome inhibitors), include bortezomib, carfilzomib, ixazomib: number of patients who were treated with at least one and were refractory to at least one.
  4. dIMiDs (immunomodulatory imide drugs) include thalidomide, lenalidomide and pomalidomide. A number of patients were treated with at least one and were refractory to at least one.
  5. eAnti-CD38 mAb include daratumumab and isatuximab. A number of patients were treated with at least one of the two drugs and were refractory to at least one.
  6. fPI and IMiD and Anti-CD38 mAb, patients who were treated with at least one PI, one immunomodulatory drug and one anti-CD38 mAb and were refractory to at least one of each.
Back to article page